drugset / Trial / NCT03233243

Rosuvastatin Effect on Atherosclerotic Plaque Metabolism

NCT03233243 ↗

Phase 4 Completed 40 enrolled University of Coimbra AstraZeneca · collab
Non-randomizedSingle-groupDouble-blindPrevention

Summary

Atherosclerotic plaque uptake of 18F-sodium fluoride (NaF) in positron emission tomography with computed tomography (PET-CT) was recently shown to correlate with clinical instability in patients with CV disease. We hypothesize that rosuvastatin reduces 18F-NaF plaque uptake. Our group will scan coronary, aortic and carotid arteries of high-risk CV subjects with 18F- NaF-PET-CT. Individuals with 18F-NaF-positive plaques will be treated with rosuvastatin for six months, followed by 18F-NaF-PET-CT re-evaluation.

Timeline

Start
2020-07-27
Primary completion
2022-06-20
Completion
2022-10-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Rosuvastatin Small molecule 40 mg Oral

Indications